Related Experiment Videos
Ceftriaxone no longer predictably cures chancroid in Kenya
M Tyndall1, M Malisa, F A Plummer
1Department of Medicine, University of Manitoba, Winnipeg, Canada.
The Journal of Infectious Diseases
|February 1, 1993
Summary
Current ceftriaxone treatment for chancroid is failing in 35% of cases in Kenya. Human immunodeficiency virus type 1 (HIV) infection is linked to poor outcomes, necessitating a reevaluation of treatment guidelines for this sexually transmitted infection.
Area of Science:
- Infectious Diseases
- Public Health
- Dermatology
Background:
- Chancroid is a bacterial sexually transmitted infection (STI) caused by Haemophilus ducreyi.
- Ceftriaxone 250 mg intramuscularly is the recommended treatment for chancroid.
- High treatment failure rates necessitate reevaluation of current therapeutic guidelines.
Purpose of the Study:
- To assess the efficacy of intramuscular ceftriaxone in treating culture-proven chancroid in Nairobi, Kenya.
- To identify factors associated with treatment failure in chancroid patients.
Main Methods:
- A prospective study involving 133 men with culture-proven chancroid in Nairobi, Kenya.
- Patients received a single intramuscular dose of 250 mg ceftriaxone.
- Treatment outcomes and associations with human immunodeficiency virus type 1 (HIV-1) seropositivity were analyzed.
Main Results:
- A treatment failure rate of 35% was observed among patients receiving ceftriaxone.
- Human immunodeficiency virus type 1 (HIV-1) seropositivity was significantly associated with poor treatment outcomes.
- The study highlights potential challenges in managing chancroid in populations with high HIV prevalence.
Conclusions:
- Current treatment recommendations for chancroid using ceftriaxone may require revision.
- The impact of HIV-1 co-infection on treatment efficacy warrants further investigation.
- Alternative or adjunctive therapeutic strategies for chancroid should be explored, particularly in high HIV prevalence settings.